The small molecule harmine regulates NFATc1 and Id2 expression in osteoclast progenitor cells.

[1]  B. Cha,et al.  Harmine, a β-carboline alkaloid, inhibits osteoclast differentiation and bone resorption in vitro and in vivo. , 2011, European journal of pharmacology.

[2]  W. Sippl,et al.  Activation, regulation, and inhibition of DYRK1A , 2011, The FEBS journal.

[3]  S. Rivella,et al.  Id1 Represses Osteoclast-Dependent Transcription and Affects Bone Formation and Hematopoiesis , 2009, PloS one.

[4]  W. Becker,et al.  Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation , 2009, The FEBS journal.

[5]  Hong-Hee Kim,et al.  Negative Feedback Inhibition of NFATc1 by DYRK1A Regulates Bone Homeostasis* , 2009, The Journal of Biological Chemistry.

[6]  Y. Tabata,et al.  Enhanced bone regeneration via multimodal actions of synthetic peptide SVVYGLR on osteoprogenitors and osteoclasts. , 2009, Biomaterials.

[7]  H. Takayanagi,et al.  Ca2+‐NFATc1 signaling is an essential axis of osteoclast differentiation , 2009, Immunological reviews.

[8]  Jung Ha Kim,et al.  Regulatory mechanism of NFATc1 in RANKL‐induced osteoclast activation , 2009, FEBS letters.

[9]  H. Katus,et al.  DYRK1A Is a Novel Negative Regulator of Cardiomyocyte Hypertrophy* , 2009, The Journal of Biological Chemistry.

[10]  O. MacDougald,et al.  Inhibitor of DNA binding 2 is a small molecule-inducible modulator of peroxisome proliferator-activated receptor-gamma expression and adipocyte differentiation. , 2008, Molecular endocrinology.

[11]  P. Cohen,et al.  The selectivity of protein kinase inhibitors: a further update. , 2007, The Biochemical journal.

[12]  S. Fox,et al.  RANKL-dependent and RANKL-independent mechanisms of macrophage-osteoclast differentiation in breast cancer , 2007, Breast Cancer Research and Treatment.

[13]  Paul Nghiem,et al.  Chemical genetics: elucidating biological systems with small-molecule compounds. , 2007, The Journal of investigative dermatology.

[14]  R. Damoiseaux,et al.  The small molecule harmine is an antidiabetic cell-type-specific regulator of PPARgamma expression. , 2007, Cell metabolism.

[15]  N. Ohara,et al.  Molecular analysis of RANKL‐independent cell fusion of osteoclast‐like cells induced by TNF‐α, lipopolysaccharide, or peptidoglycan , 2007, Journal of cellular biochemistry.

[16]  S. Moro,et al.  Tetrabromocinnamic Acid (TBCA) and Related Compounds Represent a New Class of Specific Protein Kinase CK2 Inhibitors , 2007, Chembiochem : a European journal of chemical biology.

[17]  Jungchan Park,et al.  Regulation of NFAT activation: a potential therapeutic target for immunosuppression. , 2006, Molecules and cells.

[18]  Y. Gwack,et al.  A genome-wide Drosophila RNAi screen identifies DYRK-family kinases as regulators of NFAT , 2006, Nature.

[19]  Xin Gao,et al.  NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21 , 2006, Nature.

[20]  Soo Young Lee,et al.  Id helix-loop-helix proteins negatively regulate TRANCE-mediated osteoclast differentiation. , 2006, Blood.

[21]  Tak W. Mak,et al.  Autoamplification of NFATc1 expression determines its essential role in bone homeostasis , 2005, The Journal of experimental medicine.

[22]  J. Steer,et al.  Thapsigargin Modulates Osteoclastogenesis Through the Regulation of RANKL‐Induced Signaling Pathways and Reactive Oxygen Species Production , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[23]  Y. Toyama,et al.  DC-STAMP is essential for cell–cell fusion in osteoclasts and foreign body giant cells , 2005, The Journal of experimental medicine.

[24]  Svetlana V Komarova,et al.  Convergent signaling by acidosis and receptor activator of NF-kappaB ligand (RANKL) on the calcium/calcineurin/NFAT pathway in osteoclasts. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Jun Jiang,et al.  LTB4 Can Directly Stimulate Human Osteoclast Formation from PBMC Independent of RANKL , 2005, Artificial cells, blood substitutes, and immobilization biotechnology.

[26]  B. DeDecker,et al.  Chemical genetics to identify NFAT inhibitors: Potential of targeting calcium mobilization in immunosuppression , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Jian Wang,et al.  Specific inhibition of cyclin-dependent kinases and cell proliferation by harmine. , 2004, Biochemical and biophysical research communications.

[28]  F. Aricioglu,et al.  Effect of Harmane on the Convulsive Threshold in Epilepsy Models in Mice , 2003, Annals of the New York Academy of Sciences.

[29]  R. Benezra,et al.  Id proteins in development, cell cycle and cancer. , 2003, Trends in cell biology.

[30]  E. Louis,et al.  TOXICOKINETICS OF TREMOROGENIC NATURAL PRODUCTS, HARMANE AND HARMINE, IN MALE SPRAGUE-DAWLEY RATS , 2001, Journal of toxicology and environmental health. Part A.

[31]  Y. Yokota.  Id and development , 2001, Oncogene.

[32]  D. Nutt,et al.  β-carboline binding to imidazoline receptors , 2001 .

[33]  R. Glennon,et al.  Binding of β-carbolines and related agents at serotonin (5-HT2 and 5-HT1A), dopamine (D2) and benzodiazepine receptors , 2000 .

[34]  T. Sourkes,et al.  "Rational hope" in the early treatment of Parkinson's disease. , 1999, Canadian journal of physiology and pharmacology.

[35]  Ahmed Mansouri,et al.  Development of peripheral lymphoid organs and natural killer cells depends on the helix–loop–helix inhibitor Id2 , 1999, Nature.

[36]  J. Woo,et al.  Ca2+-ATPase inhibitors and Ca2+-ionophore induce osteoclast-like cell formation in the cocultures of mouse bone marrow cells and calvarial cells. , 1997, Biochemical and biophysical research communications.

[37]  H. Yatani,et al.  A Small-molecule Approach to Bone Regenerative Medicine in Dentistry , 2010 .

[38]  D. Nutt,et al.  beta-carboline binding to imidazoline receptors. , 2001, Drug and alcohol dependence.

[39]  R. Glennon,et al.  Binding of beta-carbolines and related agents at serotonin (5-HT(2) and 5-HT(1A)), dopamine (D(2)) and benzodiazepine receptors. , 2000, Drug and alcohol dependence.

[40]  H. Joost,et al.  Structural and functional characteristics of Dyrk, a novel subfamily of protein kinases with dual specificity. , 1999, Progress in nucleic acid research and molecular biology.

[41]  R. Ramsay,et al.  Inhibition of Monoamine Oxidase A by β-Carboline Derivatives , 1997 .